gilead sciences

gilead sciences

NASDAQ:GILD

Chart

Detailed Quote

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.
CEO Interviews
Featured Articles and Interviews
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2026

Double helix DNA with word "ETFs" and biotech stock tickers.

5 Small-cap Biotech ETFs to Watch in 2026

Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Press Releases

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-1 Inhibitors

INNspired

*Disclaimer: This profile is sponsored by Gilead Sciences ( NASDAQ:GILD ). This profile provides information which was sourced by the Investing News Network (INN) and approved by Gilead Sciences in order to help investors learn more about the company. Gilead Sciences is a client of INN. The company's campaign fees pay for INN to create and update this profile.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

This profile contains forward-looking information, including statements regarding planned activities, timelines, business objectives, and market conditions. Forward-looking information is based on assumptions and is subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. Readers should not place undue reliance on forward-looking information, which reflects the views of the profiled company as of the date of this profile and is not updated by INN.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Gilead Sciences and seek advice from a qualified investment advisor.